Cipla Limited — Azithromycin Exporter Profile
Indian Pharmaceutical Exporter · #5 for Azithromycin · $8.4M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Azithromycin with $8.4M in export value and 208 verified shipments. Cipla Limited holds a 4.6% market share in Azithromycin exports across 12 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Azithromycin Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Azithromycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $1.8M | 58 | 31.2% |
| SOUTH AFRICA | $1.5M | 31 | 24.8% |
| OMAN | $733.1K | 15 | 12.5% |
| MALAYSIA | $595.4K | 20 | 10.1% |
| TURKEY | $497.5K | 63 | 8.5% |
| JAMAICA | $298.7K | 9 | 5.1% |
| IRAQ | $150.0K | 3 | 2.5% |
| SINGAPORE | $130.4K | 5 | 2.2% |
| KENYA | $122.5K | 10 | 2.1% |
| FRANCE | $37.8K | 5 | 0.6% |
Cipla Limited exports Azithromycin to 12 countries. The largest destination is SRI LANKA accounting for 31.2% of Cipla Limited's Azithromycin shipments, followed by SOUTH AFRICA (24.8%) and OMAN (12.5%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Azithromycin from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $1.4M | 44 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $713.7K | 16 |
| CAPITAL PHARMACY | OMAN | $683.1K | 14 |
| CIPLA MALAYSIA SDN BHD | MALAYSIA | $595.4K | 20 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $420.5K | 13 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $350.0K | 7 |
| ROZ LOGISTICS PALMIYE MAHALLESI | TURKEY | $253.3K | 25 |
| ROZ LOGISTICS | TURKEY | $244.3K | 38 |
| LASCO DISTRIBUTORS LTD | JAMAICA | $205.6K | 5 |
| MEDPRO PHARMACEUTICA PTY LIMITED | SOUTH AFRICA | $200.0K | 4 |
Cipla Limited supplies Azithromycin to 28 buyers globally. The largest buyer is BREATHEFREE LANKA PVT LTD (SRI LANKA), followed by MEDPRO PHARMACEUTICA (PTY) LTD (SOUTH AFRICA) and CAPITAL PHARMACY (OMAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Azithromycin Export Value and How Much Does Cipla Limited Contribute?
India exported $74.0M worth of Azithromycin through 15,000 shipments from 853 suppliers to 169 countries, serving 2,397 buyers globally. Cipla Limited contributes $8.4M to this total, accounting for 4.6% of India's Azithromycin exports. Cipla Limited ships Azithromycin to 12 countries through 28 buyers.
What Is the Average Shipment Value for Cipla Limited's Azithromycin Exports?
Cipla Limited's average Azithromycin shipment value is $40.3K per consignment, based on 208 shipments totaling $8.4M. The largest destination is SRI LANKA (31.2% of Cipla Limited's Azithromycin exports).
How Does Cipla Limited Compare to Other Indian Azithromycin Exporters?
Cipla Limited ranks #5 among 853 Indian Azithromycin exporters with a 4.6% market share. The top 3 exporters are LUPIN LIMITED ($11.0M), ALEMBIC PHARMACEUTICALS LIMITED ($8.7M), CIPLA LIMITED ($8.4M). Cipla Limited processed 208 shipments to 12 destination countries.
What Azithromycin Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| AZEE 500MG TABLET (AZITHROMYCIN DIHYDRAT | $400.0K | 8 |
| AZEE 500 TABLET (AZITHROMYCIN DIHYDRATE | $250.0K | 5 |
| AZEE 250MG TABLET ( AZITHROMYCIN DIHYDR | $181.2K | 7 |
| AZEE 500 MG TABLET (AZITHROMYCIN DIHYDRA | $165.6K | 6 |
| AZEE 500 TABLET AZITHROMYCIN DIHYDRATE DOCUMENT QTY 165150 PACK 1X3S = 495450NOS | $150.0K | 3 |
| AZEE 500MG TABLET (AZITHROMYCIN DIHYDRATE) 33267 PACK 10 X 3'SNOS | $150.0K | 3 |
| CIPLA - AZITHROMYCIN 500 INJ (AZITHROMYCIN DIHYDRATE LYOPHILIZED INJECTABLE 500MG)(1X500MG (10ML) | $144.2K | 3 |
| AZEE 500 TABLET (AZITHROMYCIN DIHYDRATE500 MG) . (INV.QTY.32520 PACK 1X3S=97560 NOS)NOS | $137.8K | 3 |
| AZEE 500 MG TAB AZITHROMYCIN DIHYDRATE500 MG . INV.QTY.4977 PACK 10X3S=149310 NOS | $133.6K | 3 |
| AZEE 500 MG TABLET (AZITHROMYCIN DIHYDRATE) (INV.QTY.18360 PACK 10X3S=550800 NOS)NOS | $107.0K | 3 |
Cipla Limited exports 105 distinct Azithromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is AZEE 500MG TABLET (AZITHROMYCIN DIHYDRAT with 8 shipments worth $400.0K.
Regulatory Requirements: Exporting Azithromycin to Key Markets
What Cipla Limited must comply with to export Azithromycin to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Azithromycin Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | LUPIN LIMITED | $11.0M | 220 | 2 | $50.0K |
| 4 | ALEMBIC PHARMACEUTICALS LIMITED | $8.7M | 174 | 2 | $50.0K |
| 5 | CIPLA LIMITED ★ | $8.4M | 208 | 12 | $40.3K |
| 6 | JUBILANT GENERICS LIMITED | $6.9M | 164 | 14 | $42.2K |
| 7 | ZYDUS LIFESCIENCES LIMITED | $6.0M | 161 | 8 | $37.3K |
Cipla Limited ranks #5 among 853 Indian Azithromycin exporters. Average shipment value of $40.3K compared to the market average of $86.8K. The closest competitors by value are LUPIN LIMITED and ALEMBIC PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Azithromycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 2,394 | 16.0% |
| SAHAR AIR | 2,211 | 14.7% |
| DELHI AIR CARGO ACC (INDEL4) | 1,693 | 11.3% |
| DELHI AIR | 1,106 | 7.4% |
| JNPT/ NHAVA SHEVA SEA | 902 | 6.0% |
| NHAVA SHEVA SEA (INNSA1) | 870 | 5.8% |
| Bombay Air | 618 | 4.1% |
| JNPT | 408 | 2.7% |
What Other Antibiotics Products Does Cipla Limited Export?
Cipla Limited also exports these antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Azithromycin Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Azithromycin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Azithromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Azithromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 229 individual customs records matching Cipla Limited exporting Azithromycin, covering 105 formulations to 12 countries via 28 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 169+ countries, 2,397+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Azithromycin Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Azithromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Azithromycin Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Azithromycin. For current shipment-level data, contact TransData Nexus.